79544-31-3

Basic information

• Product Name: 3,4-DINITROBENZYL ALCOHOL
• Synonyms: 3,4-DINITROBENZYL ALCOHOL;(3,4-Dinitrophenyl)methanol;benzenemethanol, 3,4-dinitro-;EINECS 279-178-9;ZINC06091872
• CAS NO: 79544-31-3
• Molecular Formula: C₇H₆N₂O₅
• Molecular Weight: 198.13
• EINECS: 279-178-9
• Product Categories: Benzhydrols, Benzyl & Special Alcohols
• Mol File: 79544-31-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 433.1°C at 760 mmHg
• Flash Point: 197.1°C
• Appearance: /
• Density: 1.56g/cm³
• Vapor Pressure: 2.85E-08mmHg at 25°C
• Refractive Index: 1.641
• PKA: 13.26±0.10(Predicted)
• CAS DataBase Reference: 3,4-DINITROBENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DINITROBENZYL ALCOHOL(79544-31-3)
• EPA Substance Registry System: 3,4-DINITROBENZYL ALCOHOL(79544-31-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 79544-31-3(Hazardous Substances Data)

Usage

Description

3,4-DINITROBENZYL ALCOHOL, also known as (3,4-dinitrophenyl)methanol, is an organic compound characterized by the presence of two nitro groups (-NO2) at the 3rd and 4th positions on a benzene ring, with a hydroxyl group (-OH) attached to the benzylic carbon. This chemical structure endows it with unique properties that make it a versatile intermediate in the synthesis of various organic compounds.

Uses

Used in Pharmaceutical Industry:
3,4-DINITROBENZYL ALCOHOL is used as a synthetic intermediate for the preparation of pyrazolyl benzimidazole derivatives, which are of significant interest in the development of anticancer agents. These derivatives have the potential to target and inhibit the growth of cancer cells, offering new therapeutic options for cancer treatment.
In the synthesis of pyrazolyl benzimidazole derivatives, 3,4-DINITROBENZYL ALCOHOL serves as a key building block, allowing for the creation of diverse chemical structures with potential anticancer properties. Its reactivity and functional groups make it an essential component in the development of novel and effective pharmaceutical compounds.

InChI:InChI=1/C7H6N2O5/c10-4-5-1-2-6(8(11)12)7(3-5)9(13)14/h1-3,10H,4H2

Upstream product

• 528-45-0 3,4-dinitrobenzoic acid 

Downstream Products

• 137626-72-3 3',4'-dinitrobenzyl 9,10-dimethoxyanthracene-2-sulfonate 
• 63189-98-0 1,2-diamino-4-hydroxymethylbenzene 
• 89692-62-6 3,4-Dinitrobenzyl chloride 
• 251643-67-1 N-[2-(N,N-Dimethylamino)ethyl] 4-[N-methyl-N-(3,4-dinitrobenzyloxycarbonyl)amino]phenylacetamide 
• 79591-52-9 (6R,7R)-3-Acetoxymethyl-7-(5-hydroxymethyl-1H-benzoimidazol-2-ylamino)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 35998-98-2 2,4-dinitrobenzaldehyde 
• 114872-53-6 4-(bromomethyl)-1,2-dinitrobenzene 

Relevant articles and documents

PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES

A compound represented by the general Formula (I), whereinhydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents -X-Q-P, wherein X is absent or represents –CH2-, –C(O)-, or –C(O)NH-(CH2)k-, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight-or branched-chain C1-C3 alkyl, –(CH2)l-NR2R3, or–(CH2)m-C(O)-NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent;and R2and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6- membered saturated heterocyclicring, wherein one of carbon atoms can be replaced with oxygen, -NH-or –N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases. (I)

Catalytic asymmetric syntheses of tyrosine surrogates

(Chemical Equation Presented) Amino acid esters 5-11 as tyrosine mimics have been synthesized in excellent enantioselectivity (up to 99.6% ee) and in good overall chemical yields. The key step in the sequence was the Burk's [Rh(COD)(2R,5R)-Et-DuPhos]BF4-catalyzed asymmetric hydrogenation of enamides with a variety of reactive functional groups.

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.